Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2018

01-12-2018 | Original article

Dipstick proteinuria and all-cause mortality among the general population

Authors: Kunitoshi Iseki, Tsuneo Konta, Koichi Asahi, Kunihiro Yamagata, Shouichi Fujimoto, Kazuhiko Tsuruya, Ichiei Narita, Masato Kasahara, Yugo Shibagaki, Toshiki Moriyama, Masahide Kondo, Chiho Iseki, Tsuyoshi Watanabe

Published in: Clinical and Experimental Nephrology | Issue 6/2018

Login to get access

Abstract

Background

Dipstick proteinuria, but not albuminuria, is used for general health screening in Japan. How the results of dipstick proteinuria tests correlate with mortality and, however, is not known.

Methods

Subjects were participants of the 2008 Tokutei-Kenshin (Specific Health Check and Guidance program) in six districts in Japan. On the basis of the national database of death certificates from 2008 to 2012, we used a personal identifier in two computer registries to identify participants who might have died. The hazard ratio (95% confidence interval, CI) was calculated by Cox-proportional hazard analysis.

Results

Among a total of 140,761 subjects, we identified 1641 mortalities that occurred by the end of 2012. The crude mortality rates were 1.1% for subjects who were proteinuria (−), 1.5% for those with proteinuria (+/−), 2.0% for those with proteinuria (1+), 3.5% for those with proteinuria (2+), and 3.7% for those with proteinuria (≥ 3+). After adjusting for sex, age, body mass index, estimated glomerular filtration rate, comorbid condition, past history, and lifestyle, the hazard ratio (95% CI) for dipstick proteinuria was 1.262 (1.079–1.467) for those with proteinuria (+/−), 1.437 (1.168–1.748) for those with proteinuria (1+), 2.201 (1.688–2.867) for those with proteinuria (2+), and 2.222 (1.418–3.301) for those with proteinuria (≥ 3+) compared with the reference of proteinuria (−).

Conclusion

Dipstick proteinuria is an independent predictor of death among Japanese community-based screening participants.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423–9.CrossRef Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423–9.CrossRef
2.
go back to reference Yu TY, Li HY, Jiang YD, Chang TJ, Wei JN, Chuang LM. Proteinuria predicts 10-year cancer-related mortality in patients with type 2 diabetes. J Diabetes Complic. 2013;27:201–7.CrossRef Yu TY, Li HY, Jiang YD, Chang TJ, Wei JN, Chuang LM. Proteinuria predicts 10-year cancer-related mortality in patients with type 2 diabetes. J Diabetes Complic. 2013;27:201–7.CrossRef
3.
go back to reference Mok Y, Matsushita K, Sang Y, Ballew SH, Grams M, Shin SY, et al. Association of kidney disease measures with cause-specific mortality: the Korean Heart Study. PLoS One. 2016;11:e0153429.CrossRef Mok Y, Matsushita K, Sang Y, Ballew SH, Grams M, Shin SY, et al. Association of kidney disease measures with cause-specific mortality: the Korean Heart Study. PLoS One. 2016;11:e0153429.CrossRef
4.
go back to reference Wang J, Li J, Wang A, Yang Y, Chen S, Wu S, et al. Dipstick proteinuria and risk of myocardial infarction and all-cause mortality in diabetes or pre-diabetes: a population-based cohort study. Sci Rep. 2017;7:11986.CrossRef Wang J, Li J, Wang A, Yang Y, Chen S, Wu S, et al. Dipstick proteinuria and risk of myocardial infarction and all-cause mortality in diabetes or pre-diabetes: a population-based cohort study. Sci Rep. 2017;7:11986.CrossRef
5.
go back to reference Wen CP, Cheng TYD, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462293 adults in Taiwan. Lancet. 2008;371:2173–82.CrossRef Wen CP, Cheng TYD, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462293 adults in Taiwan. Lancet. 2008;371:2173–82.CrossRef
6.
go back to reference Tanihara S, Hayakawa T, Oki I, Nakamura Y, Sakata K, Okayama A, et al. Proteinuria is a prognostic marker for cardiovascular mortality: NIPPON DATA 80, 1980–1999. J Epidemiol. 2005;15:146–53.CrossRef Tanihara S, Hayakawa T, Oki I, Nakamura Y, Sakata K, Okayama A, et al. Proteinuria is a prognostic marker for cardiovascular mortality: NIPPON DATA 80, 1980–1999. J Epidemiol. 2005;15:146–53.CrossRef
7.
go back to reference Nagata M, Ninomiya T, Kiyohara Y, Murakami Y, Irie F, Sairenchi T, et al. Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals from 7 cohort studies in Japan. Am J Epidemiol. 2013;178:1–11.CrossRef Nagata M, Ninomiya T, Kiyohara Y, Murakami Y, Irie F, Sairenchi T, et al. Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals from 7 cohort studies in Japan. Am J Epidemiol. 2013;178:1–11.CrossRef
8.
go back to reference Sato H, Konta T, Ichikawa K, Suzuki N, Kabasawa A, Suzuki K, et al. Comparison of the predictive ability of albuminuria and dipstick proteinuria for mortality in the Japanese population: the Yamagata (Takahata) study. Clin Exp Nephrol. 2016;20:611–7.CrossRef Sato H, Konta T, Ichikawa K, Suzuki N, Kabasawa A, Suzuki K, et al. Comparison of the predictive ability of albuminuria and dipstick proteinuria for mortality in the Japanese population: the Yamagata (Takahata) study. Clin Exp Nephrol. 2016;20:611–7.CrossRef
9.
go back to reference Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375:905–6.CrossRef Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375:905–6.CrossRef
10.
go back to reference Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRef Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRef
11.
go back to reference Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.CrossRef Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.CrossRef
12.
go back to reference Weng PH, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol. 2011;6:1121–8.CrossRef Weng PH, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol. 2011;6:1121–8.CrossRef
13.
go back to reference Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis. 2004;44(5 Suppl 2):16–21.CrossRef Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis. 2004;44(5 Suppl 2):16–21.CrossRef
14.
go back to reference Iseki K, Asahi K, Moriyama T, Yamagata K, Tsuruya K, Yoshida H, et al. Risk factor profiles based on estimated glomerular filtration rate and dipstick proteinuria among participants of the Specific Health Check and Guidance System in Japan 2008. Clin Exp Nephrol. 2012;16:244–9.CrossRef Iseki K, Asahi K, Moriyama T, Yamagata K, Tsuruya K, Yoshida H, et al. Risk factor profiles based on estimated glomerular filtration rate and dipstick proteinuria among participants of the Specific Health Check and Guidance System in Japan 2008. Clin Exp Nephrol. 2012;16:244–9.CrossRef
15.
go back to reference Iseki K, Asahi K, Yamagata K, Fujimoto S, Tsuruya K, Narita I, et al. Mortality risk among screened subjects of the Specific Health Check and Guidance Program in Japan 2008–2012. Clin Exp Nephrol. 2017;21(6):978–85.CrossRef Iseki K, Asahi K, Yamagata K, Fujimoto S, Tsuruya K, Narita I, et al. Mortality risk among screened subjects of the Specific Health Check and Guidance Program in Japan 2008–2012. Clin Exp Nephrol. 2017;21(6):978–85.CrossRef
16.
go back to reference Iseki K, Konta T, Asahi K, Yamagata K, Fujimoto S, Tsuruya K, et al. Association of dipstick hematuria with all-cause mortality in the general population: results from the Specific Health Check and Guidance Program in Japan. Nephrol Dial Transpl. 2017. https://doi.org/10.1093/ndt/gfx213.CrossRef Iseki K, Konta T, Asahi K, Yamagata K, Fujimoto S, Tsuruya K, et al. Association of dipstick hematuria with all-cause mortality in the general population: results from the Specific Health Check and Guidance Program in Japan. Nephrol Dial Transpl. 2017. https://​doi.​org/​10.​1093/​ndt/​gfx213.CrossRef
18.
go back to reference Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.CrossRef Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.CrossRef
19.
go back to reference Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality: a meta-analysis from the CKD Prognosis Consortium. JAMA. 2014;311:2518–31.CrossRef Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality: a meta-analysis from the CKD Prognosis Consortium. JAMA. 2014;311:2518–31.CrossRef
20.
go back to reference Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRef Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRef
21.
go back to reference Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama Study. Hypertension. 2006;47:149–54.CrossRef Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama Study. Hypertension. 2006;47:149–54.CrossRef
22.
go back to reference Matsushita K. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis of general population cohorts. Lancet. 2010;375(9731):2073–81.CrossRef Matsushita K. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis of general population cohorts. Lancet. 2010;375(9731):2073–81.CrossRef
23.
go back to reference Wang G, Staplin N, Emberson J, Baigen C, Turner R, Chalmers J, et al. Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer. 2016;16:488.CrossRef Wang G, Staplin N, Emberson J, Baigen C, Turner R, Chalmers J, et al. Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer. 2016;16:488.CrossRef
24.
go back to reference Hoogeveen EK, Geleijnse JM, Giltay EJ, Soedamah-Muth SS, de Goede J, Oude Griep LM, et al. Kidney function and specific mortality in 60–80 years old post-myocardial infarction patients: a 10-year follow-up study. PLos One. 2017;12(2):e0171868.CrossRef Hoogeveen EK, Geleijnse JM, Giltay EJ, Soedamah-Muth SS, de Goede J, Oude Griep LM, et al. Kidney function and specific mortality in 60–80 years old post-myocardial infarction patients: a 10-year follow-up study. PLos One. 2017;12(2):e0171868.CrossRef
25.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef
26.
go back to reference Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and the diagnostic standard for metabolic syndrome. Nihon Naika Gakkai Zasshi 2005;94:794–809 (Japanese).CrossRef Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and the diagnostic standard for metabolic syndrome. Nihon Naika Gakkai Zasshi 2005;94:794–809 (Japanese).CrossRef
27.
go back to reference Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig. 2012;3:39–40.CrossRef Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig. 2012;3:39–40.CrossRef
28.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRef
29.
go back to reference Lowrance WT, Ordoñez J, Udaltsova N, Russo P, Go AS. CKD and the risk of incident cancer. J Am Soc Nephrol. 2014;25:2327–34.CrossRef Lowrance WT, Ordoñez J, Udaltsova N, Russo P, Go AS. CKD and the risk of incident cancer. J Am Soc Nephrol. 2014;25:2327–34.CrossRef
30.
go back to reference Jørgensen L, Heuch I, Jenssen T, Jacobsen BK. Association of albuminuria and cancer incidence. J Am Soc Nephrol. 2008;19:992–8.CrossRef Jørgensen L, Heuch I, Jenssen T, Jacobsen BK. Association of albuminuria and cancer incidence. J Am Soc Nephrol. 2008;19:992–8.CrossRef
31.
go back to reference Kondo M, Yamagata K, Hoshi SL, Saito C, Asahi K, Moriyama T, et al. Budget impact analysiof chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2014;18:885–91.CrossRef Kondo M, Yamagata K, Hoshi SL, Saito C, Asahi K, Moriyama T, et al. Budget impact analysiof chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2014;18:885–91.CrossRef
32.
go back to reference de Jager DJ, Vervloet MG, Dekker FW. Noncardiovascular mortality in CKD: an epidemiological perspective. Nat Rev Nephrol. 2014;10:208–14.CrossRef de Jager DJ, Vervloet MG, Dekker FW. Noncardiovascular mortality in CKD: an epidemiological perspective. Nat Rev Nephrol. 2014;10:208–14.CrossRef
33.
go back to reference Konta T, Hao Z, Takasaki S, Abiko H, Ishikawa M, Takahashi T, et al. Clinical utility of trace proteinuria for microalbuminuria screening in the general population. Clin Exp Nephrol. 2007;11:51–5.CrossRef Konta T, Hao Z, Takasaki S, Abiko H, Ishikawa M, Takahashi T, et al. Clinical utility of trace proteinuria for microalbuminuria screening in the general population. Clin Exp Nephrol. 2007;11:51–5.CrossRef
34.
go back to reference Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, et al. An overview of regular dialysis treatment in Japan (As of December 2013). Ther Apher Dial. 2015;19:540–74.CrossRef Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, et al. An overview of regular dialysis treatment in Japan (As of December 2013). Ther Apher Dial. 2015;19:540–74.CrossRef
35.
go back to reference Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int. 1997;51:850–4.CrossRef Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int. 1997;51:850–4.CrossRef
36.
go back to reference Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307:1941–51.CrossRef Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307:1941–51.CrossRef
37.
go back to reference Imai E, Yamagata K, Iseki K, Iso H, Horio M, Makino H, et al. Kidney disease screening program in Japan: history, outcome, and perspectives. Clin J Am Soc Nephrol. 2007;2:1360–6.CrossRef Imai E, Yamagata K, Iseki K, Iso H, Horio M, Makino H, et al. Kidney disease screening program in Japan: history, outcome, and perspectives. Clin J Am Soc Nephrol. 2007;2:1360–6.CrossRef
38.
go back to reference Nagai K, Sairenchi T, Irie F, Watanabe H, Ota H, Yamagata K. Relationship between estimated glomerular filtration rate and cardiovascular mortality in a Japanese cohort with long-term follow-up. PLoS One. 2016;11:e0156792.CrossRef Nagai K, Sairenchi T, Irie F, Watanabe H, Ota H, Yamagata K. Relationship between estimated glomerular filtration rate and cardiovascular mortality in a Japanese cohort with long-term follow-up. PLoS One. 2016;11:e0156792.CrossRef
39.
go back to reference Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91:227–34.CrossRef Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91:227–34.CrossRef
40.
go back to reference Konta T, Ichikawa K, Ikeda A, Fujimoto S, Iseki K, Moriyama T, et al. Blood pressure control in a Japanese population with chronic kidney disease: a baseline survey of a nationwide cohort. Am J Hypertens. 2012;25:342–7.CrossRef Konta T, Ichikawa K, Ikeda A, Fujimoto S, Iseki K, Moriyama T, et al. Blood pressure control in a Japanese population with chronic kidney disease: a baseline survey of a nationwide cohort. Am J Hypertens. 2012;25:342–7.CrossRef
41.
go back to reference Yano Y, Sato Y, Fujimoto S, Konta T, Iseki K, Moriyama T, et al. Association of high pulse pressure with proteinuria in subjects with diabetes, pre-diabetes or normal glucose tolerance in a large Japanese general population sample. Diabetes Care. 2012;35:1310–5.CrossRef Yano Y, Sato Y, Fujimoto S, Konta T, Iseki K, Moriyama T, et al. Association of high pulse pressure with proteinuria in subjects with diabetes, pre-diabetes or normal glucose tolerance in a large Japanese general population sample. Diabetes Care. 2012;35:1310–5.CrossRef
42.
go back to reference Yano Y, Fujimoto S, Kramer H, Sato Y, Konta T, Iseki K, et al. Long-term blood pressure variability, new-onset diabetes, and new-onset chronic kidney disease in the Japanese general population. Hypertension. 2015;66:30–6.CrossRef Yano Y, Fujimoto S, Kramer H, Sato Y, Konta T, Iseki K, et al. Long-term blood pressure variability, new-onset diabetes, and new-onset chronic kidney disease in the Japanese general population. Hypertension. 2015;66:30–6.CrossRef
43.
go back to reference Tsuruya K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of chronic kidney disease: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66:972–83.CrossRef Tsuruya K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of chronic kidney disease: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66:972–83.CrossRef
44.
go back to reference Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870–6.CrossRef Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870–6.CrossRef
45.
go back to reference Kovesdy CP, Coresh J, Ballew SH, Woodward M, Levin A, Naimark DM, et al. Past decline versus current eGFR and subsequent ESRD risk. J Am Soc Nephrol. 2015;27:2447–55.CrossRef Kovesdy CP, Coresh J, Ballew SH, Woodward M, Levin A, Naimark DM, et al. Past decline versus current eGFR and subsequent ESRD risk. J Am Soc Nephrol. 2015;27:2447–55.CrossRef
46.
go back to reference Carrero JJ, Grams ME, Sang Y, Ärnlöv J, Gasparini A, Matsushita K, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int. 2017;91:244–51.CrossRef Carrero JJ, Grams ME, Sang Y, Ärnlöv J, Gasparini A, Matsushita K, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int. 2017;91:244–51.CrossRef
47.
go back to reference Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349–60.CrossRef Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349–60.CrossRef
48.
go back to reference Wakasugi M, Kazama JJ, Narita I, Iseki K, Fujimoto S, Moriyama T, et al. Association between overall lifestyle changes and the incidence of proteinuria: a population-based, cohort study. Intern Med. 2017;56(12):1475–84.CrossRef Wakasugi M, Kazama JJ, Narita I, Iseki K, Fujimoto S, Moriyama T, et al. Association between overall lifestyle changes and the incidence of proteinuria: a population-based, cohort study. Intern Med. 2017;56(12):1475–84.CrossRef
49.
go back to reference Yamagata K, Makino H, Iseki K, Ito S, Kimura K, Kusano E, et al. Effects of behaviour modification on outcome in early- to moderate-stage chronic kidney disease: a cluster-randomized trial. PLoS One. 2016;11:e0151422.CrossRef Yamagata K, Makino H, Iseki K, Ito S, Kimura K, Kusano E, et al. Effects of behaviour modification on outcome in early- to moderate-stage chronic kidney disease: a cluster-randomized trial. PLoS One. 2016;11:e0151422.CrossRef
50.
go back to reference Hallan SI, Øvrehus MA, Romundstad S, Rifkin D, Langhammer A, Stevens PE, et al. Long-term trends with prevalence of chronic kidney disease and the influence of cardiovascular risk factors in Norway. Kidney Int. 2016;90:665–73.CrossRef Hallan SI, Øvrehus MA, Romundstad S, Rifkin D, Langhammer A, Stevens PE, et al. Long-term trends with prevalence of chronic kidney disease and the influence of cardiovascular risk factors in Norway. Kidney Int. 2016;90:665–73.CrossRef
51.
go back to reference Jha V, Arici M, Collins AJ, Garcia-Garcia G, Hemmelgarn BR, Jafar TH, et al. Understanding kidney care needs and implementation strategies in low- and middle-income countries: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90:1164–74.CrossRef Jha V, Arici M, Collins AJ, Garcia-Garcia G, Hemmelgarn BR, Jafar TH, et al. Understanding kidney care needs and implementation strategies in low- and middle-income countries: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90:1164–74.CrossRef
52.
go back to reference Perkovic V, Agarwal R, Fioretto P, Hemmelgarn BR, Levin A, Thomas MC, et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90:1175–83.CrossRef Perkovic V, Agarwal R, Fioretto P, Hemmelgarn BR, Levin A, Thomas MC, et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90:1175–83.CrossRef
53.
go back to reference Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.CrossRef Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.CrossRef
54.
go back to reference Gansevoort RT, de Jong PE, Postma MJ. Cost-effectiveness of screening for proteinuria. JAMA. 2004;291:1442–3.PubMed Gansevoort RT, de Jong PE, Postma MJ. Cost-effectiveness of screening for proteinuria. JAMA. 2004;291:1442–3.PubMed
Metadata
Title
Dipstick proteinuria and all-cause mortality among the general population
Authors
Kunitoshi Iseki
Tsuneo Konta
Koichi Asahi
Kunihiro Yamagata
Shouichi Fujimoto
Kazuhiko Tsuruya
Ichiei Narita
Masato Kasahara
Yugo Shibagaki
Toshiki Moriyama
Masahide Kondo
Chiho Iseki
Tsuyoshi Watanabe
Publication date
01-12-2018
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 6/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-018-1587-x

Other articles of this Issue 6/2018

Clinical and Experimental Nephrology 6/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.